ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1388

Diagnostic Accuracy of Anti-dsDNA Antibodies in Unselected Patients with Recent Onset of Rheumatic Symptoms

Michele Compagno1, Søren Jacobsen2, Ole Petter Rekvig3, Lennart Truedsson4, Niels H. H. Heegaard5, Johannes C. Nossent6, Andreas Jönsen1, Rasmus Sleimann Jacobsen7, Gro Østli Eilertsen6, Gunnar K. Sturfelt8 and Anders Bengtsson1, 1Department of clinical sciences - Rheumatology, Lund University, Lund, Sweden, 2Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 3Department of Biochemistry and Medical Biology, University Hospital, Tromsø, Norway, 4Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund University, Lund, Sweden, 5Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark, 6Dept of Rheumatology, University of Tromsø, Tromso, Norway, 7Department of Infectious Diseases and Rheumatology, Section 4242, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 8Department of Rheumatology, University Hospital Lund, Lund, Sweden

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-dsDNA, autoantibodies, autoimmune diseases, laboratory tests and multicenter study

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: Anti-dsDNA antibodies are widely used in diagnostic settings when SLE is suspected. Crithidia Luciliae Immunofluorescence Test (CLIFT) and Enzyme Linked ImmunoSorbent Assay (ELISA) are commonly used assays to detect anti-dsDNA antibodies in clinical practice. The aim of the present study was to evaluate the diagnostic accuracy of CLIFT and ELISA in unselected patients with recent onset of rheumatic symptoms.

Methods: In the three participating centres, 1073 consecutive patients were locally screened for ANA. A total of 292 ANA positive patients and 292 matching ANA negative patients were selected. Anti-dsDNA antibodies were assessed at study entry by different laboratories with CLIFT (totally four times using two different commercial kits) and with ELISA (totally four times with three different commercial kits). The results of the laboratory tests were related to the clinical diagnosis formulated at study entry and verified after a long term follow-up period (median 4.8 years).

Results: Discrepant results were obtained from the different assessments regardless of the assay used, with kappa statistics value ranging between 0.25 and 0.75. At least one anti-dsDNA analysis was positive in 164 patients, but in only seven patients the positivity was confirmed by all the assessments. SLE diagnosis was initially made in 65 patients, of which 40 were anti-dsDNA positive. A wide spectrum of other diagnoses was observed among anti-dsDNA positive patients. Overall, about one third of anti-dsDNA positive patients were ANA negative. At follow-up after approximately 5 years, SLE diagnosis was unchanged in 63 patients (39 anti-dsDNA positive) and changed in only two (one anti-dsDNA positive). Among the 120 anti-dsDNA positive patients not diagnosed with SLE at study entry, only one developed SLE during the follow-up period.

Conclusion: Regardless of the assay used, assessment of anti-dsDNA antibodies was not reliable as diagnostic tool in our cohort of unselected patients with rheumatic symptoms. ANA showed poor reliability as screening test before anti-dsDNA analysis. Anti-dsDNA antibodies had surprisingly low positive predictive value for SLE diagnosis, despite their high specificity. For non SLE patients, being anti-dsDNA positive poses little risk of developing SLE within 5 years.


Disclosure:

M. Compagno,
None;

S. Jacobsen,
None;

O. P. Rekvig,
None;

L. Truedsson,
None;

N. H. H. Heegaard,
None;

J. C. Nossent,
None;

A. Jönsen,
None;

R. Sleimann Jacobsen,
None;

G. Eilertsen,
None;

G. K. Sturfelt,
None;

A. Bengtsson,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diagnostic-accuracy-of-anti-dsdna-antibodies-in-unselected-patients-with-recent-onset-of-rheumatic-symptoms/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology